Milan Gojgić

Dr. Milan Gojgić

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
Marija BrankovićMarija Branković
Marija Branković
Tijana GmizićTijana Gmizić
Tijana Gmizić
MDMarija Dukić
Marija Dukić
MZMarija Zdravković
Marija Zdravković
BDBranislava Vojislav Daskalovic
Branislava Vojislav Daskalovic
Zoran TodorovicZoran Todorovic
Zoran Todorovic
Palmitoylethanolamide (PEA) is an endocannabinoid-like bioactive lipid mediator belonging to the family of N-acylethanolamines, most abundantly found in peanuts and egg yolk. When the gastrointestinal (GI) effects of PEA are discussed, it must be pointed out that it affects intestinal motility but also modulates gut microbiota. This is due to anti-inflammatory, antioxidant, analgesic, antimicrobial, and immunomodulatory features. Additionally, PEA has shown beneficial effects in several GI diseases, particularly irritable bowel syndrome and inflammatory bowel diseases, as various studies have shown, and it is important to emphasize its relative lack of toxicity, even at high dosages. Unfortunately, there is not enough endogenous PEA to treat disturbed gut homeostasis, even though it is produced in the GI tract in response to inflammatory stimuli, so exogenous intake is mandatory to achieve homeostasis. Intake of PEA could be through animal and/or vegetable food, but bearing in mind that a high dosage is needed to achieve a therapeutic effect, it must be compensated through dietary supplements. There are still open questions pending to be answered, so further studies investigating PEA’s effects and mechanisms of action, especially in humans, are crucial to implementing PEA in everyday clinical practice.

26 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SPSnjezana Petrovic
Snjezana Petrovic
Danijela Ristic-MedicDanijela Ristic-Medic
Danijela Ristic-Medic
Marija PaunovicMarija Paunovic
Marija Paunovic
BPBiljana Pokimica
Biljana Pokimica
MKMilica Kojadinovic
Milica Kojadinovic
Vesna VucicVesna Vucic
Vesna Vucic
Background: Endocrine therapies are accompanied by side effects that significantly impact the quality of life (QoL) of women with breast cancer. Adequate diet is important for fulfilling nutritional requirements, preserving health, and supporting therapy in this vulnerable population. Methods: This preliminary study evaluated the QoL of life and dietary intake in 185 women with breast cancer on two therapies, aromatase inhibitors (AIs) and tamoxifen, using the Functional Assessment of Cancer Therapy—Endocrine Symptoms (FACT-ES), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Breast Cancer Specific Questionnaire (QLQ-BR23) and a 24 h dietary recall. A total of 185 women were included in the study and fulfilled the FACT-ES, of whom 73 fulfilled other two questionnaires and a 24 h recall. Results: No significant differences were found in the overall QoL between groups. Joint pain (95.3%) and reduced libido (84.7%) were most common with AIs, while tamoxifen users more frequently reported weight gain and irritability (93.0%, each), and vasomotor and gynecological symptoms. Macronutrient intake was similar, though AIs users consumed more energy-dense (p ≤ 0.001) and sugary foods (p = 0.034), while tamoxifen users had higher omega-6 PUFA intake. Both groups exhibited suboptimal intake of vitamin D, calcium, and selenium, and a higher phosphorus consumption relative to recommended daily values. Conclusions: Preliminary findings showed that QoL and dietary intake were comparable between patients with BC on AIs and tamoxifen treatment. Endocrine-related symptoms were more prevalent among tamoxifen users, whereas joint pain was most common in AIs users. Nutritional interventions may be warranted in both groups to ensure adequate intake of essential micronutrients in accordance with recommended dietary guidelines.

1 January 2025 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
DZDarko Zdravkovic
Darko Zdravkovic
Barbara LobodaBarbara Loboda
Barbara Loboda
MGMilan Gojgić
Milan Gojgić
BTBorislav Toskovic
Borislav Toskovic
Breast cancer is the most frequent cancer among women worldwide. Cancer cells primarily spread through the lymphatic vessels, with axillary lymph node status being one of the most reliable prognostic factors in breast cancer patients. Axillary lymph node staging in breast cancer patients was initially performed by axillary lymph node dissection. Sentinel lymph node biopsy is the standard of care in clinically and radiologically negative axilla. According to the current guidelines, double contrast is a recommended procedure for identifying the sentinel lymph node. Nowadays, several new tracers are in clinical practice with a high identification rate and low false negative results. Due to technological and resource limitations, many medical centers worldwide lack the facilities to apply new radioactive tracers. The use of blue dye alone is a reliable and effective diagnostic and surgical technique, offering a high identification rate and low false-negative results.

17 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DBDragana Bjelica
Dragana Bjelica
NCNatasa Dusan Colakovic
Natasa Dusan Colakovic
SOSvetlana Opric
Svetlana Opric
DZDarko Zdravkovic
Darko Zdravkovic
Barbara LobodaBarbara Loboda
Barbara Loboda
NINebojsa Ivanovic
Nebojsa Ivanovic
Background: We present a detailed description and the preliminary results of our original technique for non-invasive three-dimensional tumor localization in the breast, which was created as an alternative to standard invasive tumor marking before neoadjuvant systemic therapy (NAST), aiming to enable adequate surgery after complete tumor regression. Methods: A detailed description of the technique is provided in the main text. The technique’s feasibility and precision were assessed in a single-arm, prospective study based on the histological parameters of the adequacy and rationality of the excision of completely regressed tumor beds. Results: Out of 94 recruited patients, 15 (16%) were deemed unsuitable, mainly due to the tumors’ inadequate ultrasound visibility. Among the 79 processed patients, 31 (39%) had complete clinical regression after NAST and were operated on using our technique. The histological parameters of surgical precision (signs of tumor regression: 24/31; microscopic cancer residues: 7/31) were verified in all excised specimens (100% precision). There were no positive margins in seven cases with microscopic residues, indicating our technique’s capacity to enable oncologically safe post-NAST surgery. Conclusions: The proposed technique is feasible and satisfactorily accurate in determining the location of regressed tumors, thus representing an alternative to invasive tumor marking, especially in surgical centers lacking trained staff and equipment for invasive marking. The technique’s limitations are mainly related to the inadequate ultrasound visibility of the tumor.

1 January 2026 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
BVBojana Vidovic
Bojana Vidovic
ASAna Sekulic
Ana Sekulic
SPSanja Vignjevic Petrinovic
Sanja Vignjevic Petrinovic
NCNatasa Dusan Colakovic
Natasa Dusan Colakovic
SPSimona Petricevic
Simona Petricevic
DZDarko Zdravkovic
Darko Zdravkovic
Introduction/Objective. Subclinical inflammation is increasingly recognized as a driver of postoperative pain, yet its role in breast tumour surgery is not fully defined. The objective was to determine whether preoperative C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) predict acute postoperative pain (APSP); to examine how surgical extent influences the peri-operative inflammatory response; and to explore the relation between intra-operative fentanyl and pain intensity. Methods. In a prospective single-centre cohort, 101 adults scheduled for breast surgery were stratified into four groups: mastectomy (M, n = 25), tumourectomy (T, n = 28), tumourectomy plus axillary dissection (T+A, n = 20), and benign excision (C, n = 28). Venous blood was drawn on admission (T0) and at 24 h (T24) for CRP and ESR. Pain was assessed with an 11-point Numerical Rating Scale 30 min after recovery and at 24 h; the highest 24-h score (max-APSP) was the primary pain outcome. Results. Pre-operative CRP correlated with max-APSP (p = 0.043), whereas ESR did not (p = 0.11). Baseline CRP and ESR, and their 24-h increments, rose stepwise with surgical magnitude, peaking after mastectomy (baseline CRP 7.1 ± 1.9 mg/L; T24 27.5 ± 3.6 mg•L/¹; both p < 0.01 vs. other groups). Intra-operative fentanyl correlated with CRP at 24 h (r = 0.33, p = 0.001) and with max-APSP (r = 0.28, p = 0.005). Despite these biological gradients, mean max-APSP remained mild to moderate across groups. Conclusion. Pre-surgical systemic inflammation, reflected by CRP, independently predicts early pain after breast tumour surgery. Surgical magnitude amplifies inflammatory markers, and greater fentanyl exposure parallels both inflammation and pain. Routine perioperative CRP may help identify high-risk patients for targeted anti-inflammatory and opioid-sparing analgesic strategies to reduce acute pain and potentially mitigate chronic pain development.

2 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
DZDarko Zdravkovic
Darko Zdravkovic
Barbara LobodaBarbara Loboda
Barbara Loboda
SPSimona Petricevic
Simona Petricevic
MGMilan Gojgić
Milan Gojgić
NCNatasa Dusan Colakovic
Natasa Dusan Colakovic
VNVladimir Nikolić
Vladimir Nikolić
Background/Objectives: Predicting sentinel lymph node (SLN) involvement in breast cancer can reduce unnecessary axillary lymph node dissections (ALND) and facilitate clinical decision-making. This study aimed to: (i) identify independent predictors for SLN metastasis, and (ii) assess the predictive performance of the MSKCC nomogram for SLN positivity in early-stage breast cancer patients. Methods: A retrospective cohort study spanning a six-year period was conducted at a tertiary care oncology department in Belgrade, Serbia. The study included 684 consecutive patients with histologically confirmed primary breast carcinoma, without distant metastasis, who underwent surgical treatment with sentinel lymph node biopsy (SLNB). Results: Out of 684 patients, 198 (29%) were SLN-positive. Among the positive cases, 178 (89.9%) had one positive SLN, 19 (9.6%) had two, and 1 (0.5%) had three. Multivariate logistic regression revealed that lymphovascular invasion and tumor sizes >20 mm significantly increased the risk for SLN involvement. Patients with SLN metastasis had significantly higher MSKCC-predicted probabilities compared to SLN-negative patients (52.1 ± 18.5% vs. 33.1 ± 16.9%, p < 0.001). The area under the receiver operating characteristic curve (AUC) for the nomogram was 0.778 (95% CI: 0.738–0.818; p < 0.001). The nomogram demonstrated acceptable discrimination, with an AUC of 0.778 (95% CI: 0.738–0.818). However, calibration-in-the-large was −0.526 (95% CI: −0.709 to −0.342), indicating systematic overestimation of absolute risk. The calibration slope was 1.152 (95% CI: 0.921–1.383), and the Brier score was 0.174. Conclusions: Lymphovascular invasion and primary tumor size >20 mm are the only independent predictors of SLN metastasis. Furthermore, The MSKCC nomogram demonstrated acceptable discrimination but systematically overestimated absolute SLN-metastasis risk. Recalibration and further validation are required before clinical application in this population.